BC Extra | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

CymaBay lost three quarters of its market value Monday after atypical histological findings prompted it to hold its lead program and discontinue two more trials, all developing seladelpar for liver indications. The $4.22 (76%) decline...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
BC Week In Review | Jun 24, 2013
Company News

Dara BioSciences, T3D deal

Dara granted T3D exclusive, worldwide rights to develop and commercialize DB959 for $500,000 in initial license fees. The dual PPAR delta and gamma agonist has completed Phase I testing to treat diabetes and dyslipidemia. T3D...
BC Week In Review | Nov 21, 2011
Clinical News

DB959: Phase Ib data

A double-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial in 32 healthy volunteers showed that once-daily DB959 for 7 days was well tolerated. Furthermore, Dara said that changes in circulating adiponectin (ADIPOQ) , a biomarker of PPAR...
BC Week In Review | Apr 11, 2011
Clinical News

DB959: Phase Ib started

Dara BioSciences began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 5, 20 and 100 mg oral DB959 once daily for 7 days in 24 patients. Dara licensed the compound from Bayer in 2007...
BC Week In Review | Jan 10, 2011
Clinical News

DB959: Additional Phase I data

Additional data from a double-blind, dose-escalation U.S. Phase I trial in 76 healthy volunteers showed that the maximum tolerated dose of DB959 was not reached. The highest dose tested in the trial was 200 mg,...
BC Week In Review | Nov 22, 2010
Clinical News

DB959: Phase I data

A double-blind, U.S. Phase I trial in 76 healthy volunteers showed that single ascending-doses of oral DB959 exhibited a safety profile comparable to that of placebo, with no moderate, severe or serious adverse events reported....
BC Week In Review | Apr 5, 2010
Clinical News

DB959: Phase I started

Dara began a single ascending-dose, U.S. Phase I trial to evaluate oral DB959 in about 75 healthy volunteers. Dara licensed the compound from Bayer in 2007. Dara BioSciences Inc. (NASDAQ:DARA), Raleigh, N.C.   Bayer AG...
BC Week In Review | Nov 16, 2009
Clinical News

Dara BioSciences preclinical data

In mouse models of diabetes, DB959 significantly lowered blood glucose levels and improved glucose tolerance compared with baseline. The company expects to begin Phase I testing of the dual peroxisome proliferation activated receptor (PPAR) delta...
BC Innovations | Oct 8, 2009
Targets & Mechanisms

New role for Actos in MS

Industry has targeted peroxisome proliferation-activated receptors for metabolic indications since the 1990s. Now, a paper by German researchers suggests the PPAR agonist Actos pioglitazone could be useful for treating multiple sclerosis and other autoimmune diseases....
Items per page:
1 - 10 of 15